Note: Ingredients listed on restricted chemical lists
EC/CAS
111-46-6
Name of the chemical
diethyleneglycol
Concentration
30 ≤C < 100
EC/CAS
203-872-2/110-97-4
Name of the chemical
1,1'-iminodipropan-2-ol
Concentration
1-<10
General Information
Revision date
2022-06-24
Product name
Brake Fluid Dot 4
Product Synonyms
BRAKE FLUID DOT 4
supplier name
Ford-Werke GmbH
Emergency telephone
+49 (0) 6132-84463 (GBK GmbH – 24/7
Icons in SDS
Company Information
company name
Ford-Werke GmbH
e-mail address of the competent person responsible for the Safety Data Sheet
sdseu@ford.com
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H361d
Hazard statements
Code
Statements
H361d
Suspected of damaging the unborn child
Section 2
EU Classification
Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations
Health hazards
Reproductive toxicity, Category 2 H361d Suspected of damaging the unborn child. Full text of H- and EUH-statements: see section 16
Adverse physicochemical, human health and environmental effects
No additional information available
2.2 Label elements
Labelling according to The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations
Signal word
Warning
Contains
Tris[2-[2-(2-methoxyethoxy)ethoxy]ethyl] orthoborate
Hazard statements
H361d Suspected of damaging the unborn child.
Prevention
P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. P280 Wear eye protection, protective clothing, face protection, protective gloves
Response
P308+P313 IF exposed or concerned: Get medical advice/attention.
2.3 Other hazards
This substance/mixture does not meet the PBT criteria of REACH regulation, annex XIII. This substance/mixture does not meet the vPvB criteria of REACH regulation, annex XIII. The mixture does not contain substance(s) included in the list established in accordance with Article 59(1) of REACH for having endocrine disrupting properties, or is not identified as having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at a concentration equal to or greater than 0,1 %